Share on StockTwits

Dendreon (NASDAQ:DNDN)‘s stock had its “neutral” rating reaffirmed by Zacks in a research note issued to investors on Thursday. They currently have a $1.50 price target on the stock. Zacks‘s target price suggests a potential upside of 5.63% from the company’s current price.

Zacks’ analyst wrote, “The news of a probable default by Dendreon was disappointing and pretty much eclipsed second quarter results. Although Dendreon has sufficient cash to meet its ordinary course obligations for at least the next twelve months, the company will surely not be able to repay or refinance its debt due in 2016. Dendreon reported a net loss of $0.10 in the second quarter of 2014, narrower than the Zacks Consensus Estimate of $0.18 and the year-ago loss of $0.45. Total revenue in the reported quarter was up 12.1% year over year to $82.2 million and beat the Zacks Consensus Estimate of $74 million. The departure of the company’s CEO further increases the uncertainty surrounding Dendreon. We maintain our Neutral recommendation on the stock.”

Shares of Dendreon (NASDAQ:DNDN) traded down 0.70% on Thursday, hitting $1.41. The stock had a trading volume of 3,463,923 shares. Dendreon has a one year low of $1.24 and a one year high of $3.52. The stock has a 50-day moving average of $2.12 and a 200-day moving average of $2.48. The company’s market cap is $225.7 million.

Dendreon (NASDAQ:DNDN) last announced its earnings results on Monday, August 11th. The company reported ($0.10) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.25) by $0.15. The company had revenue of $82.16 million for the quarter, compared to the consensus estimate of $73.37 million. During the same quarter last year, the company posted ($0.45) earnings per share. Dendreon’s revenue was up 12.1% compared to the same quarter last year. Analysts expect that Dendreon will post $-0.78 EPS for the current fiscal year.

A number of other firms have also recently commented on DNDN. Analysts at R. F. Lafferty downgraded shares of Dendreon from a “buy” rating to a “neutral” rating in a research note on Wednesday. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Dendreon in a research note on Wednesday. They now have a $1.50 price target on the stock, down previously from $2.50. Finally, analysts at Roth Capital reiterated a “sell” rating on shares of Dendreon in a research note on Tuesday. Eight analysts have rated the stock with a sell rating and ten have given a hold rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $2.24.

Dendreon Corporation (NASDAQ:DNDN) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients.

To view Zacks’ full report, visit Zacks’ official website.

Receive News & Ratings for Dendreon Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dendreon Co and related companies with Analyst Ratings Network's FREE daily email newsletter.